New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis
Open Access
- 26 March 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320441
Abstract
Galectin-9 (Gal-9) has gained increasing attention in recent years in the field of cancer immunology. Its interactions with various immune cell types in the tumor microenvironment influence tumor progression, making it a novel target for immunotherapy. Despite its potential as a therapeutic target, the prognostic significance of Gal-9 in tumor cells remains unclear. Conflicting data exists on its expression levels and outcomes, prompting a comprehensive review and meta-analysis to elucidate its independent prognostic role across different cancer types. This study aims to examine the varying effects of Gal-9 expression across various cancer subtypes, providing insights into its potential as a prognostic marker and highlighting its significance in the realm of cancer treatment. To assess the prognostic significance of Gal-9 expression in cancer, we conducted a comprehensive database search across PubMed, Embase, and Web of Science, incorporating studies published until December 2024, regardless of language. Using pooled hazard ratios (HRs) with 95% confidence intervals (CIs), we evaluated the role of Gal-9 expression in predicting cancer outcomes across various cancer types. Our analysis encompassed 29 studies with a total of 4,720 patients to investigate the prognostic significance of Gal-9 expression across different cancer types. The results demonstrated that elevated Gal-9 expression was significantly associated with improved overall survival (OS) in solid tumors, with a pooled hazard ratio of 0.75 (95% CI: 0.63-0.90, p = 0.002). No statistically significant correlation was observed between Gal-9 expression and cancer recurrence (HR = 0.88, 95% CI: 0.65–1.19, p = 0.42). Conversely, in hematological cancers, high Gal-9 expression correlated with more rapid disease progression, as reflected by progression-free survival (PFS) or time to treatment (TTT) (HR = 2.29, 95% CI: 1.26–4.16, p = 0.007). The subgroup analyses further revealed that higher Gal-9 expression was associated with OS in gastrointestinal and urological cancers and was linked to disease-free survival (DFS) and recurrence-free survival (RFS) in hepatobiliary and urological cancers. Our research has uncovered that Gal-9 serves as a promising prognostic indicator for solid tumors, offering valuable insights into patient outcomes. High levels of Gal-9 expression within gastrointestinal, hepatobiliary, and urological cancers have been linked to better prognoses, while its presence in hematological cancers is associated with poorer outcomes. These contrasting findings emphasize the importance of interpreting biomarkers with careful consideration to the specific context. Moreover, our study sheds light on the diverse physiological roles of intracellular and secreted Gal-9, highlighting the intricate ways in which this protein influences cancer progression.Keywords
Funding Information
- Croucher Foundation (Ref. No.9509002 and 9500032)
- Science, Technology and Innovation Commission of Shenzhen Municipality (JCYJ20210324133813036)
- Hong Kong Research Grants Council (Ref.No. C7008-22G and 11103523)
- Tung Biomedical Sciences Centre (Ref. No. 9609306)
- City University of Hong Kong (Ref. No. 7005313, 7005518, 7005740, and 7005873)
This publication has 61 references indexed in Scilit:
- Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancerJournal of Surgical Oncology, 2024
- CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemiaAnnals of Hematology, 2023
- Galectin‐9 and myeloid‐derived suppressor cell as prognostic indicators for chronic lymphocytic leukemiaImmunity, Inflammation and Disease, 2023
- Galectin-8 and -9 as prognostic factors for cervical cancerArchives of Gynecology and Obstetrics, 2022
- Galectin-9 as a biomarker of disease severityCellular Immunology, 2021
- Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinomaCancer Immunology, Immunotherapy, 2020
- The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia CellsEBioMedicine, 2017
- Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancerInternational Journal of Cancer, 2017
- Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinomaTumor Biology, 2015
- Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T CellsImmunity, 2014